X

Trial Profile

Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil plus darunavir regimen

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 19 Oct 2016

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Darunavir (Primary) ; Elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat (Primary)
Indications HIV-1 infections
Focus Adverse reactions; Therapeutic Use

Most Recent Events

19 Oct 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com